Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review

Osteonecrosis of the jaw (ONJ) is one of the most relevant and specific complication of biphosphonates. ONJ in patients receiving zoledronic acid every 3 to 4 weeks is frequently described, but the ONJ biyearly regimen used to reduce aromatase inhibitor associated bone loss (AIBL), is rarely reporte...

Descripción completa

Detalles Bibliográficos
Autores principales: Kourie, Hampig Raphael, Antoun, Joelle, El Rassy, Elie, Rassy, Marc, Sader-Ghorra, Claude, Kattan, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648993/
https://www.ncbi.nlm.nih.gov/pubmed/26587372
http://dx.doi.org/10.1016/j.jbo.2015.09.001
Descripción
Sumario:Osteonecrosis of the jaw (ONJ) is one of the most relevant and specific complication of biphosphonates. ONJ in patients receiving zoledronic acid every 3 to 4 weeks is frequently described, but the ONJ biyearly regimen used to reduce aromatase inhibitor associated bone loss (AIBL), is rarely reported. A literature review, focusing on the important trials using zoledronic acid to reduce AIBL, found that the mean risk of developing ONJ when zoledronic acid is used biyearly varies between 0.12% and 0.7%.

Ejemplares similares